Persistent Dark Cones in Oligocone Trichromacy Revealed by Multimodal Adaptive Optics Ophthalmoscopy.
adaptive optics
color vision
dark cones
oligocone trichromacy
optical coherence tomography
pde6h
scanning laser ophthalmoscopy
visual function
Journal
Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
11
2020
accepted:
09
02
2021
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
27
3
2021
Statut:
epublish
Résumé
Dark cone photoreceptors, defined as those with diminished or absent reflectivity when observed with adaptive optics (AO) ophthalmoscopy, are increasingly reported in retinal disorders. However, their structural and functional impact remain unclear. Here, we report a 3-year longitudinal study on a patient with oligocone trichromacy (OT) who presented with persistent, widespread dark cones within and near the macula. Diminished electroretinogram (ERG) cone but normal ERG rod responses together with normal color vision confirmed the OT diagnosis. In addition, the patient had normal to near normal visual acuity and retinal sensitivity. Occasional dark gaps in the photoreceptor layer were observed on optical coherence tomography, in agreement with reflectance AO scanning light ophthalmoscopy, which revealed that over 50% of the cones in the fovea were dark, increasing to 74% at 10° eccentricity. In addition, the cone density was 78% lower than normal histologic value at the fovea, and 20-40% lower at eccentricities of 5-15°. Interestingly, color vision testing was near normal at locations where cones were predominantly dark. These findings illustrate how a retina with predominant dark cones that persist over at least 3 years can support near normal central retinal function. Furthermore, this study adds to the growing evidence that cones can continue to survive under non-ideal conditions.
Identifiants
pubmed: 33767618
doi: 10.3389/fnagi.2021.629214
pmc: PMC7985087
doi:
Types de publication
Journal Article
Langues
eng
Pagination
629214Informations de copyright
Copyright © 2021 Li, Liu, Flynn, Turriff, Liu, Ullah, Liu, Dubra, Johnson, Brooks, Hufnagel, Hammer, Huryn, Jeffrey and Tam.
Déclaration de conflit d'intérêts
ZL has a patent on adaptive optics-optical coherence tomography technology and stand to benefit financially from any commercialization of the technology. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Vis. 2002;2(5):404-12
pubmed: 12678654
Doc Ophthalmol. 2009 Feb;118(1):69-77
pubmed: 19030905
Vision Res. 1998 Nov;38(21):3413-9
pubmed: 9893858
Nat Neurosci. 2009 Aug;12(8):967-9
pubmed: 19561602
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4431-8
pubmed: 26193919
Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4580-92
pubmed: 14507907
Invest Ophthalmol Vis Sci. 2011 Sep 21;52(10):7376-84
pubmed: 21724911
Vis Neurosci. 2004 May-Jun;21(3):431-6
pubmed: 15518225
Mol Ther. 2018 Sep 5;26(9):2282-2294
pubmed: 30196853
Biomed Opt Express. 2017 Oct 19;8(11):5098-5112
pubmed: 29188106
Am J Ophthalmol. 2012 Dec;154(6):987-1001.e1
pubmed: 22959359
J Comp Neurol. 1990 Feb 22;292(4):497-523
pubmed: 2324310
Biomed Opt Express. 2011 Jun 1;2(6):1757-68
pubmed: 21698035
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):40
pubmed: 32203983
PLoS One. 2019 Jul 25;14(7):e0211397
pubmed: 31344029
Invest Ophthalmol Vis Sci. 2014 Sep 09;55(10):6301-8
pubmed: 25205868
Hum Mutat. 2020 Jan;41(1):255-264
pubmed: 31544997
Invest Ophthalmol Vis Sci. 2013 Aug 28;54(8):5836-47
pubmed: 23908179
Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4639-4652
pubmed: 30372733
Am J Ophthalmol Case Rep. 2017 Sep;7:14-19
pubmed: 29057371
Am J Hum Genet. 2012 Sep 7;91(3):527-32
pubmed: 22901948
Genes (Basel). 2016 Jul 27;7(8):
pubmed: 27472364
Ocul Immunol Inflamm. 2020 Jan 4;:1-6
pubmed: 31902265
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4477-4489
pubmed: 28873173
Ophthalmic Physiol Opt. 2020 Mar;40(2):88-116
pubmed: 32017191
Invest Ophthalmol Vis Sci. 2014 Jun 06;55(7):4244-51
pubmed: 24906859
Invest Ophthalmol Vis Sci. 2011 Jul 01;52(7):4757-64
pubmed: 21436275
Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1234-1243
pubmed: 30924848
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT533-43
pubmed: 27472277
Biomed Opt Express. 2018 Aug 14;9(9):4246-4262
pubmed: 30615699
J Clin Invest. 2018 Dec 3;128(12):5663-5675
pubmed: 30418171